The Joe Rogan ExperienceJoe Rogan Experience #2251 - Rick Perry & W. Bryan Hubbard
CHAPTERS
- 0:00 – 1:46
Why Rick Perry & Bryan Hubbard are on: Kentucky’s ibogaine initiative and opioid settlement funds
Joe opens by asking how Rick Perry and W. Bryan Hubbard connected. Hubbard explains his public service role in Kentucky and how he designed the Kentucky Ibogaine Initiative using opioid settlement money. He credits Perry as a key advocate who helped legitimize and publicize the effort.
- •Hubbard’s role leading Kentucky’s Opioid Abatement Advisory Commission
- •Kentucky’s $842M (paid over 15 years) opioid settlement context
- •Creation of the “Kentucky Ibogaine Initiative”
- •Perry’s public support (testimonial, Newsweek op-ed)
- •Shared goal: expand access to ibogaine research/treatment
- 1:46 – 10:13
Rick Perry’s origin story: meeting Marcus Luttrell and seeing veterans fall through the cracks
Perry recounts a 2006 vacation encounter that led to a life-changing relationship with Navy SEAL Marcus Luttrell. Luttrell later arrived at the Texas governor’s mansion and ended up living with Perry’s family, exposing Perry to the realities of veterans’ trauma and inadequate government support. This experience set Perry on a long search for effective mental health solutions for veterans.
- •Coronado Island chance meeting leading to Special Warfare Center tour
- •Discovery of Marcus Luttrell’s role in Operation Red Wing
- •Luttrell shows up in Austin and lives with Perry’s family for 2.5 years
- •Perry’s firsthand exposure to gaps in veteran healthcare and benefits
- •Motivation to pursue solutions beyond conventional systems
- 10:13 – 15:04
From skeptical to outspoken: Perry’s shift toward plant medicines (and distinction from drug legalization)
Perry explains how his stance evolved from strict anti-drug views to advocating medically supervised plant medicine. He cites early exposure to medical THC for epilepsy and draws a clear line between clinical use and broad drug legalization. He frames ibogaine advocacy as evidence-driven, safety-focused, and rooted in helping veterans.
- •2013 shift after hearing a mother’s epilepsy/THC story and reviewing data
- •Separating medical, supervised use from recreational legalization debates
- •Emphasis on proper diagnosis, dosing, monitoring, and follow-up
- •Perry embraces role as a conservative messenger for plant medicine
- •Focus: veteran mental health, addiction recovery, and public education
- 15:04 – 17:35
Ads break, then ibogaine basics: not recreational, anti-addictive, and ‘rewiring’ claims
After sponsor messages, the conversation returns to ibogaine’s reputation and use-case. They emphasize it’s not a ‘party drug’ and argue it has no addiction potential while helping resolve addiction. Joe tees up the question of how ibogaine entered public awareness.
- •AG1 and ExpressVPN ad read
- •Ibogaine described as non-recreational and non-addictive
- •Claims that it can interrupt or ‘cure’ addiction pathways
- •Framing ibogaine as brain ‘reset’/rewiring medicine
- •Lead-in to ibogaine’s cultural/political history
- 17:35 – 25:16
Ibogaine’s weird public debut and the Schedule I problem: Nixon-era policy and lasting consequences
They discuss how a Hunter S. Thompson rumor helped introduce ibogaine to public discourse, then pivot to why it’s still Schedule I. Perry argues Schedule I classification is politically rooted, not medically justified, and blocks research. The discussion centers on veterans’ suicides, international access, and the push to reschedule for trials.
- •Hunter S. Thompson ‘gonzo’ story about Ed Muskie and ibogaine rumors
- •Schedule I definition vs ibogaine’s purported profile
- •Critique of Nixon-era drug scheduling as political tool
- •International contrast: Mexico/Canada/Australia/France allow use or trials
- •Veteran suicide/addiction as urgency for U.S. clinical research
- 25:16 – 34:15
Stanford/Nature Medicine study: VETS, the Ambio clinic, and reported neuroregenerative findings
Hubbard outlines the origins of VETS (Veterans Exploring Treatment Solutions) and how veterans traveled to Mexico for ibogaine treatment. He summarizes a Stanford-led study evaluating 30 veterans pre/post treatment, including MRI-based brain-age comparisons and symptom changes. They also introduce broader neurodegenerative-disease anecdotes that fuel calls for U.S. trials.
- •VETS founded by Amber and Marcus Capone; veterans sent to Mexico for treatment
- •Cohort of 30 veterans assessed with psychological batteries and MRIs
- •Reported changes: white matter thickening, growth in emotion/executive centers
- •Reported brain-age ‘reversal’ averages and top responses
- •Anecdotal expansion: Parkinson’s/MS/Lyme claims and microdosing vs flood dosing
- 34:15 – 47:03
‘Too good to be true’ vs lived experience: why Perry is willing to risk his reputation
Joe expresses skepticism that outcomes can be so consistently dramatic; Perry and Hubbard acknowledge the concern but point to repeated testimonials. Perry explains he has studied and observed clinics and is motivated by the belief that veterans’ lives outweigh political risk. They cite more public veteran advocates and the moral argument for access.
- •Joe’s concern about overpromising and audience hope
- •Perry’s personal due diligence: reading, talking to experts, visiting Mexico
- •Political consultant warns Perry about conservative ‘brand’ risk
- •Perry’s response: reputation isn’t worth more than veterans’ lives
- •Examples of public veteran stories (e.g., Marcus/Morgan Luttrell, Sean Ryan)
- 47:03 – 52:03
How ibogaine may end opioid dependence: Lotsof history, dopamine/serotonin restoration theory, and meth use-case
Hubbard gives a historical and mechanistic narrative starting with Howard Lotsof’s 1962 discovery. He frames addiction as neurochemical injury and claims ibogaine restores dopamine/serotonin production rapidly compared with the long abstinence timeline. He also notes ibogaine’s reported effectiveness for meth dependence, raising stakes in the fentanyl+meth era.
- •Howard Lotsof’s 1962 observation of opioid craving cessation
- •Addiction reframed from moral failing to neurochemical brain injury
- •Dopamine/serotonin discussion and the ‘18 months vs 48 hours’ contrast
- •Claimed success rates: 80% first administration, higher with supportive dose
- •Claim that ibogaine uniquely impacts meth dependency amid fentanyl+meth crisis
- 52:03 – 55:51
Safety realities: cardiac risk, QT prolongation, and why medical supervision matters
Hubbard emphasizes ibogaine is powerful and potentially dangerous if administered incorrectly. He explains QT prolongation and torsades risk, outlines best-practice mitigation (including magnesium), and strongly warns against self-administration or unvetted clinics. He names information resources and clinics he considers high standard.
- •Primary risk: prolonged QT interval leading to torsades/cardiac arrest
- •Need for interventional cardiology capability and ICU-level nursing support
- •Mitigation practices, including magnesium co-administration
- •Explicit warning: do not buy online or self-administer
- •Provider vetting resources and examples (Innervisions; AMBO; Beond)
- 55:51 – 1:06:28
Hubbard’s personal and professional arc: Appalachia roots, law disillusionment, and seeing opioid devastation up close
Hubbard shares his upbringing in coal country and generational trauma from addiction and untreated mental illness, alongside formative spiritual guidance from his grandfathers. He describes entering law with idealism, then practicing workers’ compensation during the opioid boom and witnessing how pain, despair, and overprescribing intertwined. This sets up his transition into Kentucky government roles focused on system performance and accountability.
- •Coal-country upbringing, family substance abuse, and early-life chaos
- •Grandfathers’ faith-based reassurance and sense of purpose
- •Law school idealism replaced by cynicism about power and outcomes
- •Workers’ comp practice during opioid surge; pattern of overmedication
- •Recognition of ‘pain’ as emotional/spiritual despair as well as physical
- 1:06:28 – 1:18:05
Kentucky government deep dive: disability growth, Medicaid prescribing metrics, corruption, and opioid-abatement opportunity
Hubbard recounts running Kentucky’s Social Security Disability system and child support enforcement, describing incentives that expand bureaucracy and dysfunction. He shares metrics on enrollment growth and prescribing increases, and details reform efforts that created political backlash. He then explains taking on opioid settlement governance and insisting on transparency to avoid ‘buzzards’ capturing the funds.
- •Disability enrollment growth vs population growth; childhood enrollment surge
- •Linking SSI/Medicaid populations to sharp increases in opioid and psychotropic dispensing
- •Critique of bureaucratic incentives (‘claims equal budget’)
- •Child support enforcement issues and reforms; political consequences
- •Opioid settlement funds framed as rare chance for a breakthrough (‘Manhattan Project’)
- 1:18:05 – 1:34:41
The Kentucky Ibogaine Initiative rises—and gets derailed: confidential NYC network, public hearings, FDA testimony, then political reversal
Hubbard details how he learned about ibogaine through psychedelic research interest, built a confidential network, and pitched ibogaine as Kentucky’s breakthrough therapeutic project. He describes three major public hearings (science, testimonials, FDA feasibility), highlighting FDA experts who said risk mitigation—not risk existence—determines trial approval. Momentum collapsed after elections and leadership changes, leading to his forced resignation.
- •Initial ibogaine introduction through writers/advocates and legal/medical networks
- •Confidential NYC convening; connecting to Capones, Nolan Williams, Alper, Mash
- •Proposal: set aside $42M in a public-private partnership for FDA pathway
- •Three public hearings: science; lived testimonials; FDA risk-mitigation testimony
- •Election-driven leadership change; ‘ambush’ resignation demand and project stall
- 1:34:41 – 1:43:43
Texas plan: legislation, funding, clinical trial roadmap, and public ROI safeguards
Perry and Hubbard pivot to Texas as the new vehicle for scaling ibogaine research, citing earlier Texas psilocybin trial legislation as precedent. They outline a proposed appropriation, solicitation of drug developers, FDA trial design, and safeguards ensuring Texans retain an interest in resulting IP. The focus is building a medically rigorous in-state infrastructure leveraging Texas’ medical institutions.
- •Texas precedent: veteran-focused psychedelic research legislation passed with broad support
- •Goal: Texas Ibogaine Initiative and timeline toward 2025 implementation
- •Proposed $50M appropriation; notice of funding opportunity to select developers
- •Designing safe trials to mitigate cardiac risk and recruit participants
- •Public return on investment: state interest in patentable IP; funding integration/support services
- 1:43:43 – 2:07:09
Broader coalition and closing themes: national state-by-state momentum, spirituality, and a call to action
They describe expanding momentum beyond Texas with other states organizing parallel efforts, and discuss how ibogaine experiences are framed as spiritually transformative. Hubbard shares personal testimony about ibogaine (and later 5-MeO-DMT) affecting his and his wife’s mental health trajectory, then broadens to a critique of dehumanizing systems. The episode ends with a call for civic engagement, public education, and prayers for success.
- •Multi-state organizing: Ohio, Washington, Arizona, New Mexico, Missouri; Kentucky salvage attempts
- •Perry’s call: contact legislators, educate public and media; veteran outreach
- •Hubbard’s personal treatment account; wife discontinuing long-term SSRI use
- •Spiritual framing: ‘affirmation’ and meaning as a societal antidote
- •Final appeal: reform broken systems, scale safe access, and sustain accountability
